Outcomes on the pharmacopsychometric triangle in bupropion‐SR vs. buspirone augmentation of citalopram in the STAR*D trial
- 12 November 2011
- journal article
- research article
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 125 (4) , 342-348
Abstract
Bech P, Fava M, Trivedi MH, Wisniewski SR, Rush AJ. Outcomes on the pharmacopsychometric triangle in bupropion‐SR vs. buspirone augmentation of citalopram in the STAR*D trial. Objective: To compare within the framework of a novel pharmacopsychometric triangle, augmentation treatment with bupropion vs. buspirone in the acute therapy of major depression in the STAR*D study. The triangle provides a composite view in three domains of antidepressive activity, side effects, and quality of life. Method: Within the pharmacopsychometric triangle, the short six‐item subscales of the Hamilton Depression Scale (HAM‐D17) and of the Inventory of Depressive Symptomatology (IDS‐C30), referred to as HAM‐D6 and IDS‐C6, were focussed on pure antidepressive effect. Side‐effects (tolerable vs. intolerable) and quality of life were measured using patient‐administered questionnaires. A modified intention to treat sample was used. Results: Within the pharmacopsychometric triangle, bupropion‐SR (sustained release) was superior to buspirone when augmented to the current citalopram treatment. Thus, in the domain of pure antidepressive effect, bupropion‐SR was superior (P = 0.05) on the HAM‐D6, IDS‐C6, and IDS‐C30, but not on the HAM‐D17. In the domain of side effects, the total scores on the Patient Rated Inventory of Side Effects (PRISE) were reduced significantly more by bupropion‐SR than by buspirone (P = 0.03). In the domain of quality of life, the total scores on the Quality of Life Enjoyment and Satisfaction Questionnaire (QLES‐Q) showed a trend (P = 0.10) from baseline to endpoint of a superiority for bupropion‐SR compared with buspirone. Conclusion: In all domains of the pharmacopsychometric triangle, bupropion‐SR was superior to buspirone as augmentation therapy in depressed outpatients not responding to citalopram.Keywords
This publication has 21 references indexed in Scilit:
- The heterogeneity of the depressive syndrome: when numbers get seriousActa Psychiatrica Scandinavica, 2011
- Refining the diagnostic criteria for major depression on the basis of empirical evidenceActa Psychiatrica Scandinavica, 2011
- Long‐term effect of combined interpersonal psychotherapy and pharmacotherapy in a randomized trial of depressed patientsActa Psychiatrica Scandinavica, 2011
- Dose–response relationship of sertindole and haloperidol using the pharmacopsychometric triangleActa Psychiatrica Scandinavica, 2011
- HAM-D17and HAM-D6Sensitivity to Change in Relation to Desvenlafaxine Dose and Baseline Depression Severity in Major Depressive DisorderPharmacopsychiatry, 2010
- Identifying Patients with Therapy-Resistant Depression by using Factor AnalysisPharmacopsychiatry, 2010
- Selective Publication of Antidepressant Trials and Its Influence on Apparent EfficacyNew England Journal of Medicine, 2008
- Efficacy of Duloxetine for the Treatment of Generalized Anxiety DisorderThe Primary Care Companion For CNS Disorders, 2007
- Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interactionInternational Clinical Psychopharmacology, 1997
- Consensus Conference on the Methodology of Clinical Trials of Antidepressants, Zurich, march 1988: Report of the Consensus CommitteePharmacopsychiatry, 1989